Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)
Notice Number:
NOT-HL-21-024

Key Dates

Release Date:

August 17, 2021

First Available Due Date:
October 16, 2021
Expiration Date:
January 08, 2025

Related Announcements

NOT-HL-20-796 - Notice of Special Interest (NOSI): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases (Reissue)

PA-20-195 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

This Notice of Special Interest is a reissue of NOT-HL-20-796.

The purpose of this NOSI is to advise potential applicants to the National Heart, Lung and Blood Institute (NHLBI) of an area of special interest to support early phases of innovative bioengineering projects which are expected to transition their research into future follow-on funding, technologies, or commercial products. Please note that this R21 program does not overlap with projects which are expected to transition their research into future follow-on funding, technologies, or commercial products. Please note that this R21 program does not overlap with the NHLBI Catalyze Program, and it does focus on new investigator-initiated ideas that will feed into the Catalyze pipeline.

Background

Why Bioengineering? The NHLBI bioengineering community has transformed medicine by creating the artificial heart, pacemakers and ICDs, VADs, stents, biosensors, human tissue chip devices and cell/gene/combination product therapies. These examples demonstrate that bioengineering is a synergistic approach that crosses not only all technology-related areas of NHLBI, but also all of our Disease-specific domains. Further, bioengineering is unique because unlike most stand-alone scientific topics, it demands collaboration across disciplines, which looks to be necessary for advancement of needed technologies. The bioengineering community’s ability to achieve alternative and more effective therapies is an urgent need for NHLBI. It is envisioned that this targeted PA will serve as an opportunity to spur truly novel ideas, address scientific gaps, and to programmatically balance bioengineering projects across the NHLBI.

Research Objectives

This Notice of Special Interest (NOSI) invites discovery- and design-driven bioengineering research ideas that are important across the Institute and that are critical for future hypothesis-generating projects. It is noteworthy that this program emphasizes development, not so much efficacy, of first-generation prototypes. The NHLBI is interested in the development of new ideas for diagnostics, therapeutics, surgical technologies, computational modeling tools, smart biomaterials for self-adjusting implants, and nanotechnologies, as applied to the cardiovascular, pulmonary, non-malignant hematologic, and sleep health mission areas of the Institute.

Topic areas are limited to early stage, non-product definition (i.e., non-Catalyze Program) exploratory research in terms of:

  • Nanotechnologies that significantly improve cellular therapeutics, diagnostic and novel medical devices
  • 3D imaging methods, including new molecular probes, for in vivo real-time monitoring, and techniques for metabolic imaging of disease progression
  • Image processing tools and methodology for big data, precision medicine, systems biology and –omics, especially for guiding interventions and patient screening
  • Gaps and Opportunities for HLBS repair and regeneration, such as genetically modifying cells for tailored medicine, and addressing reduced immunosuppression to avoid rejection for HLBS therapies
  • New biomedical algorithms to process and collect physiological signaling in vivo

Application and Submission Information

 

Submit applications for this initiative using the following funding opportunity announcement (FOA) or any reissues of the announcement through the expiration date of this NOSI.

  • PA-20-195- NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

 

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

  • For funding consideration, applicants must include “NOT-HL-21-024” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Although NHLBI is not listed as a Participating Organization in all the FOAs listed above, applications for this initiative will be accepted.

Applications nonresponsive to terms of this NOSI will be withdrawn from consideration for this initiative.

Inquiries

Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:

Scientific/Research Contact(s)

 

Narasimhan Danthi, Ph.D.
Division of Cardiovascular Sciences
Telephone: 301-435-5170
Email: ndanthi@mail.nih.gov

Martha S. Lundberg, Ph.D.
Division of Cardiovascular Sciences
Telephone: 301-435-0513
Email: lundberm@nhlbi.nih.gov

Albert Lee, Ph.D.
Division of Cardiovascular Sciences
Telephone: 301-435-0513
Email: alee@mail.nih.gov

Marishka K. Brown, Ph.D.
Division of Lung Diseases
Telephone: 301-435-0199
Email: marishka.brown@nih.gov

Qing “Sara” Lin, Ph.D.
Division of Lung Diseases
Telephone: 301-435-0222
Email: sara.lin@nih.gov

Margaret Ochocinska, Ph.D.
Division of Blood Diseases and Resources
Telephone: 301-827-8285
Email: ochocinm@mail.nih.gov

Ronald Warren, Ph.D.
Division of Blood Diseases and Resources
Telephone: 301-827-8288
Email: ronald.warren@nih.gov

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

Alyse Burton
Telephone: 301-827-8019
Email: alyse.burton@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices